文献速递认知障碍与痴呆

基于人群的认知老化研究中抗淀粉样蛋白治疗的合格性

Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
PubMed 文献 · Neurology · 2023-08-16

本研究基于Mayo Clinic衰老研究(MCSA)的237例早期阿尔茨海默病(AD)参与者,应用lecanemab和aducanumab临床试验的入排标准评估抗β-淀粉样蛋白单克隆抗体治疗的适用性。结果显示,lecanemab试验的入组标准使样本降至112例(47.3%),排除标准进一步将合格者缩至19例(8%);aducanumab试验的入组标准合格104例(43.9%),排除后仅12例(5.1%)合格。结论认为典型有认知损害的老年人中抗β-淀粉样蛋白单抗治疗的合格性有限。

要点

  • 在MCSA的237例早期AD参与者中,lecanemab试验入组标准合格112例(47.3%),排除标准后仅19例(8%)合格。
  • aducanumab试验入组标准合格104例(43.9%),排除标准后仅12例(5.1%)合格。
  • 常见排除原因与其他慢性疾病和神经影像学发现有关。

核心结论

  • 研究估计,在典型的有认知损害的老年人中,抗β-淀粉样蛋白单克隆抗体治疗的合格性有限。

研究设计与样本

  • 横断面研究,应用lecanemab和aducanumab临床试验的入排标准于基于人群的Mayo Clinic衰老研究(MCSA)中早期AD参与者,评估抗淀粉样蛋白治疗的普遍性。
  • 研究样本为237例MCSA参与者,平均年龄(标准差)80.9(6.3)岁,54.9%为男性,97.5%为白人,患有轻度认知损害(MCI)或轻度痴呆,且PiB PET显示脑淀粉样蛋白负荷增加。

主要发现

  • lecanemab试验的入组标准使研究样本减少至112例(占237例的47.3%)。
  • lecanemab试验的排除标准进一步将潜在合格参与者数目缩小至19例(占237例的8%)。
  • 修改合格标准以纳入所有MCI参与者(而非应用额外认知标准)后,17.4%的MCI参与者符合lecanemab治疗条件。
  • 104例参与者(占237例的43.9%)满足aducanumab临床试验的入组标准。
  • aducanumab试验的排除标准进一步减少可用参与者数目,使合格者缩小至12例(占237例的5.1%)。

关键数值与推荐

  • 常见排除原因与其他慢性疾病和神经影像学发现有关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Treatment options for Alzheimer disease (AD) are limited and have focused mainly on symptomatic therapy and improving quality of life. Recently, lecanemab, an anti-β-amyloid monoclonal antibody (mAb), received accelerated approval by the US Food and Drug Administration for treatment in the early stages of biomarker-confirmed symptomatic AD. An additional anti-β-amyloid mAb, aducanumab, was approved in 2021, and more will potentially become available in the near future. Research on the applicability and generalizability of the anti-β-amyloid mAb eligibility criteria on adults with biomarkers available in the general population has been lacking. The study's primary aim was to apply the clinical trial eligibility criteria for lecanemab treatment to participants with early AD of the population-based Mayo Clinic Study of Aging (MCSA) and assess the generalizability of anti-amyloid treatment. The secondary aim of this study was to apply the clinical trial eligibility criteria for aducanumab treatment in MCSA participants. METHODS: This cross-sectional study aimed to apply the clinical trial eligibility criteria for lecanemab and aducanumab treatment to participants with early AD of the population-based MCSA and assess the generalizability of anti-amyloid treatment. RESULTS: Two hundred thirty-seven MCSA participants (mean age [SD] 80.9 [6.3] years, 54.9% male, and 97.5% White) with mild cognitive impairment (MCI) or mild dementia and increased brain amyloid burden by PiB PET comprised the study sample. Lecanemab trial's inclusion criteria reduced the study sample to 112 (47.3% of 237) participants. The trial's exclusion criteria further narrowed the number of potentially eligible participants to 19 (overall 8% of 237). Modifying the eligibility criteria to include all participants with MCI (instead of applying additional cognitive criteria) resulted in 17.4% of participants with MCI being eligible for lecanemab treatment. One hundred four participants (43.9% of 237) fulfilled the aducanumab clinical trial's inclusion criteria. The aducanumab trial's exclusion criteria further reduced the number of available participants, narrowing those eligible to 12 (5.1% of 237). Common exclusions were related to other chronic conditions and neuroimaging findings. DISCUSSION: Findings estimate the limited eligibility in typical older adults with cognitive impairment for anti-β-amyloid mAbs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pittock RR, Aakre JA, Castillo AM, et al. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. Neurology. 2023. PMID: 37586881. doi:10.1212/WNL.0000000000207770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。